Cepheid:市場シェア分析...市場調査レポートについてご紹介

【英文タイトル】Cepheid Market Share Analysis

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 What Is This Report About? 11
3 Definitions of Markets/Categories Covered 12
3.1 In Vitro Diagnostics 12
3.1.1 Genetic Testing 12
3.1.2 Infectious Immunology 12
4 Company Snapshot 13
4.1 Key Facts 2011 13
4.2 Company Overview 13
4.3 Financial Performance 13
4.4 SWOT Snapshot 13
4.5 Business Overview 14
4.6 Major Products and Services 15
4.6.1 Overview 15
5 History 17
6 SWOT Analysis 19
6.1 Overview 19
6.2 Cepheid Strengths 19
6.2.1 Increasing Liquidity Ratios 19
6.2.2 The GeneXpert System 19
6.2.3 Strong In-house Research Expertise 20
6.2.4 Wide Market Applications 20
6.3 Cepheid Weaknesses 21
6.3.1 Termination of Supply Agreement with Roche 21
6.3.2 Product Recalls 21
6.3.3 Legal Proceedings 21
6.4 Cepheid Opportunities 22
6.4.1 Growth in Emerging Economies 22
6.4.2 Changing Demographics 22
6.4.3 New Product Launches and License Approvals 22
6.4.4 Inorganic Growth Strategies 22
6.5 Cepheid Threats 23
6.5.1 Cost Containment Pressures 23
6.5.2 Competitive Pressures 23
6.5.3 Government Regulations 23
6.5.4 Rapid Technological Advancements 23
7 Competitors 24
8 Competitive Landscape 25
8.1 In Vitro Diagnostics (Genetic Testing), Global, Market Share (%), 2011 25
8.2 Cepheid, In Vitro Diagnostics (Genetic Testing), by Region, Market Share (2011) 27
8.3 Cepheid, In Vitro Diagnostics (Genetic Testing), by Country, Market Share (2011) 28
8.4 In Vitro Diagnostics (Infectious Immunology), Global, Market Share (%), 2011 29
8.5 Cepheid, In Vitro Diagnostics (Infectious Immunology), by Region, Market Share (2011) 31
8.6 Cepheid, In Vitro Diagnostics (Infectious Immunology), by Country, Market Share (2011) 32
9 Cepheid Medical Equipment Market Share Analysis by Category 33
9.1 Cepheid, In Vitro Diagnostics, Global, Category Revenue Share (2011) 33
9.2 Cepheid, North America, Category Revenue Share (2011) 35
9.2.1 Cepheid, United States, Category Revenue Share (2011) 37
10 Key Employees 39
11 Key Employee Biographies 40
12 Company Statement 41
13 Locations And Subsidiaries 42
13.1 Head Office 42
13.2 Other Locations & Subsidiaries 42
14 Financial Deals Landscape 43
14.1 Cepheid, Deals Volume Summary, 2007 to YTD 2013 43
15 Cepheid Detailed Deal Summary 45
15.1 Partnerships 45
15.1.1 Cepheid Enters Into Licensing Agreement With Quantovir 45
15.1.2 Cepheid Enters Into Co-Development Agreement With FIND 46
15.1.3 Cepheid Enters Into Collaboration With Novartis 47
15.1.4 Prodesse Enters Into Distribution Agreement With Cepheid 48
15.1.5 Cepheid Enters Into Agreement With Instrumentation Lab 49
15.1.6 Biomerieux Enters Into An Agreement With Cepheid 50
15.2 Acquisition 51
15.2.1 Cepheid Acquires Stretton Scientific 51
15.2.2 Nycomed Sells Its Interest In Sangtec Molecular Diagnostic To Cepheid 52
16 Recent Developments 54
16.1 Financial Announcements 54
16.1.1 Oct 18, 2012: Cepheid Reports Revenue Of $80.6m In Q3 2012 54
16.1.2 Jul 19, 2012: Cepheid Reports Revenue Of $81m In Q2 2012 54
16.1.3 Apr 19, 2012: Cepheid Reports Revenue Of $77.3m In Q1 2012 55
16.1.4 Jan 26, 2012: Cepheid Reports Revenue Of $277.6m In 2011 55
16.1.5 Oct 20, 2011: Cepheid Reports Total Revenues Of $70.2m In Q3 2011 56
16.1.6 Jul 21, 2011: Cepheid Reports Total Revenues Of $67m In Q2 2011 56
16.1.7 Apr 20, 2011: Cepheid Reports Total Revenues Of $60.2m In Q1 2011 57
16.1.8 Jan 27, 2011: Cepheid Reports Total Revenues Of $212.46 Million In 2010 57
16.1.9 Oct 21, 2010: Cepheid Reports Total Revenues Of $56.05 Million In Q3 2010 58
16.1.10 Jul 22, 2010: Cepheid Reports Total Revenues Of $49.64 Million In Q2 2010 58
16.1.11 Apr 22, 2010: Cepheid Reports Total Revenues Of $48 Million In Q1 2010 59
16.1.12 Jan 28, 2010: Cepheid Reports Total Revenues Of $170.6 Million In 2009 59
16.1.13 Oct 28, 2009: Cepheid Reports Revenues Of $41.6 Million In Q3 2009 59
16.1.14 Jul 30, 2009: Cepheid Reports Total Revenues Of $41.02 Million In Q2 2009 60
16.1.15 Apr 23, 2009: Cepheid Posts Net Loss Of $7.4 Million, Revenues Of $44.8 million For Q1 2009 61
16.1.16 Feb 05, 2009: Cepheid Reports 2008 Results 61
16.1.17 Jan 13, 2009: Cepheid Reports Preliminary 2008 Results 62
16.1.18 Jan 13, 2009: Cepheid To Declare Full Year 2008 Results 62
16.1.19 Oct 28, 2008: Cepheid Reports 3Q 2008 Results 62
16.1.20 Oct 28, 2008: Cepheid Reports Third Quarter Revenue Of $44.9 Million 63
16.1.21 Oct 03, 2008: Cepheid To Report 3Q 2008 Results 64
16.1.22 Jul 24, 2008: Cepheid Reports 2Q 2008 Results 64
16.1.23 Jul 24, 2008: Cepheid Reports Second Quarter Revenue Of $42.1 Million 65
16.1.24 May 01, 2008: Cepheid Reports Q1 2008 Results 66
16.1.25 May 01, 2008: Cepheid Reports Record Revenue Of $44.8 Million 67
16.1.26 Apr 07, 2008: Cepheid To Report Q1 2008 Results 69
16.1.27 Feb 28, 2008: Cepheid Reports Q4 2007 Results 69
16.1.28 Feb 28, 2008: Cepheid Reports Fourth Quarter And Full Year 2007 Results 71
16.1.29 Nov 01, 2007: Cepheid Reports Third Quarter 2007 Results 73
16.1.30 Nov 01, 2007: Cepheid Reports Q3 2007 Results 73
16.1.31 Aug 07, 2007: Cepheid Reports Q2 2007 Results 75
16.1.32 Aug 07, 2007: Cepheid Reports Second Quarter 2007 Results 76
16.1.33 May 03, 2007: Cepheid Reports Q1 2007 Results 77
16.1.34 May 03, 2007: Cepheid Reports First Quarter 2007 Results 78
16.1.35 Feb 22, 2007: Cepheid Reports Q4 2006 Results 80
16.1.36 Feb 22, 2007: Cepheid Reports Fourth Quarter And Full Year 2006 Results 82
16.1.37 Nov 02, 2006: Cepheid Reports Q3 2006 Results 83
16.1.38 Nov 02, 2006: Cepheid Reports Third Quarter 2006 Results 85
16.1.39 Aug 08, 2006: Cepheid Reports Second Quarter 2006 Results 86
16.1.40 May 04, 2006: Cepheid Reports First Quarter 2006 Results 88
16.1.41 Feb 22, 2006: Cepheid Reports Fourth Quarter 2005 Results 90
16.1.42 Nov 03, 2005: Cepheid Reports Third Quarter 2005 Results 92
16.1.43 Aug 04, 2005: Cepheid Reports Second Quarter 2005 Results 93
16.1.44 May 04, 2005: Cepheid Reports First Quarter 2005 Results 95
16.1.45 Feb 28, 2005: Cepheid Reports Fourth Quarter And Fiscal Year 2004 Results 97
16.1.46 Nov 02, 2004: Cepheid Reports Third Quarter And Nine Months 2004 Results 99
16.1.47 Aug 04, 2004: Cepheid Reports Second Quarter And Six Months 2004 Results 100
16.1.48 May 05, 2004: Cepheid Reports First Quarter 2004 Results 102
16.1.49 Feb 17, 2004: Cepheid Reports Fourth Quarter And Fiscal Year 2003 Results 104
16.1.50 Jan 29, 2004: Cepheid Reports Preliminary Financial Results For Fourth Quarter And Fiscal Year 2003 106
16.1.51 Nov 04, 2003: Cepheid Reports Third Quarter And Nine Months 2003 Results 106
16.1.52 Jul 31, 2003: Cepheid Reports Second Quarter And Six Months 2003 Financial Results 108
16.1.53 Apr 30, 2003: Cepheid Reports First Quarter 2003 Results 110
16.1.54 Feb 05, 2003: Cepheid Reports Fourth Quarter And Full Year 2002 Results 111
16.1.55 Nov 06, 2002: Cepheid Reports Third Quarter 2002 Results 113
16.1.56 Jul 15, 2002: Cepheid Reports Second Quarter 2002 Financial Results 114
16.1.57 Apr 23, 2002: Cepheid Reports First Quarter 2002 Results 116
16.1.58 Feb 05, 2002: Cepheid Reports Fourth Quarter 2001 Results. 117
16.1.59 Oct 23, 2001: Cepheid Reports Third Quarter 2001 Results 118
16.1.60 Jul 24, 2001: Cepheid Reports Second Quarter 2001 Results 119
16.1.61 Apr 23, 2001: Cepheid Reports First Quarter 2001 Results 120
16.1.62 Feb 07, 2001: Cepheid Reports Fourth Quarter And Year End 2000 Results 122
16.1.63 Oct 23, 2000: Cepheid Reports Third Quarter Results 123
16.1.64 Jul 25, 2000: Cepheid Reports Second Quarter Results Initial Sales Of Smart Cycler Launched In May 124
16.2 Corporate Communications 125
16.2.1 Jun 22, 2011: Cepheid Appoints Robert Kwiatkowski As Vice President Of Infectious Disease R&D 125
16.2.2 Feb 28, 2011: Cepheid Appoints Michael Bates As Vice President Of Oncology Research And Development 125
16.2.3 Oct 13, 2009: Cepheid Appoints Nicolaas Arnold As EVP, Worldwide Commercial Operation 126
16.2.4 Oct 13, 2009: Cepheid Appoints Nicolaas Arnold As Executive Vice President Of Worldwide Commercial Operations 126
16.2.5 Feb 11, 2008: Cepheid Appoints SVP And CFO 127
16.2.6 Feb 07, 2006: Cepheid Appoints New Board Member 127
16.3 Legal and Regulatory 128
16.3.1 Sep 26, 2012: Abaxis Announces Settlement Of Patent Litigation With Cepheid 128
16.3.2 Jul 13, 2010: Cepheid Files Answer And Counterclaims In Abaxis Patent Suit 128
16.4 Product News 128
16.4.1 Dec 27, 2012: Cepheid Receives FDA Clearance For Xpert CT/NG 128
16.4.2 Aug 15, 2012: CCMC Selects Cepheid’s GeneXpert System 129
16.4.3 Aug 06, 2012: Cepheid Announces First Phase Of Xpert MTB/RIF Buy-Down For High Burden Developing Countries 130
16.4.4 Jul 25, 2012: Cepheid Announces Release Of Updated Xpert BCR-ABL Monitor Test 130
16.4.5 Jun 14, 2012: Cepheid Welcomes UNITAID Commitment To Broaden Access To Xpert MTB/RIF 131
16.4.6 May 24, 2012: Cepheid Receives FDA Clearance For GeneXpert Infinity-80 System For Initial Use With Xpert Flu Assay 132
16.4.7 May 23, 2012: Cepheid Receives CE Mark For Xpert CT 132
16.4.8 May 23, 2012: Cepheid Receives CE Mark For Xpert CT/NG 132
16.4.9 Aug 09, 2011: Cepheid Releases Updated Xpert BCR-ABL Monitor Test 133
16.4.10 Apr 26, 2011: Cepheid Receives FDA Clearance For Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 133
16.4.11 Apr 11, 2011: Cepheid Receives FDA Approval For Xpert C. difficile/Epi Test 133
16.4.12 Dec 27, 2010: Cepheid Announces European Release Of Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 134
16.4.13 Sep 02, 2010: New England Journal Of Medicine Study Reports Cepheid’s Xpert MTB/RIF Faster, More Sensitive And Specific Test For Tuberculosis 134
16.4.14 Jul 01, 2010: Cepheid Issues Recall Of Xpert MRSA/SA BC Product 135
16.4.15 Jun 08, 2010: Cepheid Receives FDA Clearance For Xpert SA Nasal Complete Molecular Test For Simultaneous Detection And Differentiation Of S. aureus And MRSA Colonization 135
16.4.16 Jan 06, 2010: Cepheid Gains FDA Approval For Its Xpert vanA/vanB 136
16.4.17 Jan 04, 2010: Cepheid Gains Emergency Use Authorization From FDA For First 2009 H1N1 Influenza Assay For CLIA Moderate Complexity Laboratories 136
16.4.18 Jul 13, 2009: US FDA Grants Approval To Cepheid’s Xpert C. difficile Test 137
16.4.19 Jun 17, 2009: Cepheid Releases Improved Xpert BCR-ABL Monitor Test In Europe 138
16.4.20 Apr 27, 2009: Cepheid Launches Xpert MTB/RIF Molecular Test In Europe 138
16.4.21 Mar 31, 2009: Cepheid Launches Xpert MRSA/SA Nasal Test In Europe 139
16.4.22 Mar 11, 2009: Cepheid’s Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License 139
16.4.23 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections 139
16.4.24 Nov 10, 2008: Cepheid Launches First On-Demand Molecular Diagnostic Test For Clostridium Difficile Into European Market 140
16.4.25 Nov 04, 2008: Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized ‘Moderate Complexity’ By FDA 140
16.4.26 Oct 07, 2008: Cepheid (CPHD) Announces CE IVD Release Of First On-Demand Test For van A/van B Genes 141
16.4.27 Oct 01, 2008: Cepheid Receives FDA Clearance For First On-Demand Diagnostic Test For Life-Threatening MRSA And Staphylococcus Aureus 141
16.4.28 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus 141
16.4.29 Jul 29, 2008: Cepheid Introduces GeneXpert Infinity-48 System At 2008 American Association Of Clinical Chemistry Meeting 142
16.4.30 Jul 28, 2008: Cepheid GeneXpert System Selected For Upto 11 Victoria, Australia Hospitals In Rollout Of Start Clean Strategy 142
16.4.31 Jul 28, 2008: Cepheid Xpert MRSA Selected In Rollout Of Start Clean Strategy 143
16.4.32 Jun 03, 2008: Cepheid (CPHD) Market Reach Extended With Licenses In Canada And Registrations In Mexico EV Test Menu In Canada And Mexico 143
16.4.33 Jun 03, 2008: Cepheid (CPHD) Market Reach Extended With Licenses In Canada And Registrations In Mexico GBS Test Menu In Canada And Mexico 143
16.4.34 Apr 03, 2008: Cepheid Selected As Vendor Of Choice By Connecticut Hospital Association Shared Services Program For Molecular MRSA Surveillance Testing 144
16.4.35 Jan 29, 2008: Cepheid Receives Health Canada Medical Device License For Xpert MRSA Test And GeneXpert System 144
16.4.36 Jan 07, 2008: Cepheid Begins Shipment Of Next Generation GeneXpert Molecular Diagnostic Systems 145
16.4.37 Dec 04, 2007: Cepheid Launches New GeneXpert Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus 146
16.5 Product Approvals 146
16.5.1 Dec 27, 2012: Cepheid Receives FDA Clearance For Xpert CT/NG 146
16.5.2 May 23, 2012: Cepheid Receives CE Mark For Xpert CT 147
16.5.3 Apr 26, 2011: Cepheid Receives FDA Clearance For Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 147
16.5.4 Apr 11, 2011: Cepheid Receives FDA Approval For Xpert C. difficile/Epi Test 147
16.5.5 Jun 08, 2010: Cepheid Receives FDA Clearance For Xpert SA Nasal Complete Molecular Test For Simultaneous Detection And Differentiation Of S. aureus And MRSA Colonization 148
16.5.6 Jan 06, 2010: Cepheid Gains FDA Approval For Its Xpert vanA/vanB 148
16.5.7 Jan 04, 2010: Cepheid Gains Emergency Use Authorization From FDA For First 2009 H1N1 Influenza Assay For CLIA Moderate Complexity Laboratories 149
16.5.8 Jul 13, 2009: US FDA Grants Approval To Cepheid’s Xpert C. difficile Test 149
16.5.9 Mar 11, 2009: Cepheid’s Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License 150
16.5.10 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections 150
16.5.11 Nov 04, 2008: Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized ‘Moderate Complexity’ By FDA 151
16.5.12 Oct 07, 2008: Cepheid (CPHD) Announces CE IVD Release Of First On-Demand Test For van A/van B Genes 151
16.5.13 Oct 01, 2008: Cepheid Receives FDA Clearance For First On-Demand Diagnostic Test For Life-Threatening MRSA And Staphylococcus Aureus 151
16.5.14 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus 152
16.5.15 Jan 29, 2008: Cepheid Receives Health Canada Medical Device License For Xpert MRSA Test And GeneXpert System 152
16.6 Clinical Trials 153
16.6.1 Sep 02, 2010: New England Journal Of Medicine Study Reports Cepheid’s Xpert MTB/RIF Faster, More Sensitive And Specific Test For Tuberculosis 153
16.7 Other Significant Developments 153
16.7.1 Jun 29, 2011: ‘Art Meets Innovation’ Event Teams Cepheid With Paul Jr Designs For Unveiling of New Products At 2011 AACC/ASCLS Meeting 153
16.7.2 May 18, 2011: Cepheid Signs Distribution Agreement With LABSCO In US 154
17 Appendix 155
17.1 Research Methodology 156
17.2 Secondary Research 156
17.3 Primary Research 156
17.4 Models 157
17.5 Forecasts 157
17.6 Expert Panels 157
17.7 GlobalData Consulting 157
17.8 Currency Conversion 158
17.9 Contact Us 159
17.10 Disclaimer 159


【レポート販売概要】

■ タイトル:Cepheid:市場シェア分析
■ 英文:Cepheid Market Share Analysis
■ 発行日:2013年2月15日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160379
■ 調査対象地域:グローバル
  • ジャム/ゼリー/保存食の世界市場2016-2020
    About Jams, Jellies, and Preserves The use of jams, jellies, and preserves is increasing in salads, cookies, pizzas, sandwiches, and smoothies as customers are willing to expand their taste pallet. In the new era, where healthy eating is becoming the prime motive of many consumers, the vendors increase their sales by focusing on products that are both indulgent, have high fruit content, and/or are …
  • スマートグリッド市場分析:Analyzing the Smart Grid
    Today’s electric power grid is primarily composed of central generating stations and electromechanical power delivery systems operated from control centers. However, the system is transforming itself into a smart grid that integrates a multitude of distributed energy resources, uses solid state electronics to manage and deliver power, and employs automated control systems. The smart grid will achi …
  • 熱可塑性ポリウレタンの世界市場予測(~2021年):ポリエステル、ポリエーテル、ポリカプロラクトン
    The thermoplastic polyurethane (TPU) market is projected to reach USD 2.48 Billion by 2021, at a CAGR of 6.8% between 2016 and 2021, in terms of value. The market has witnessed moderate growth in the recent years and this growth is projected to persist in the coming years as well. Thermoplastic polyurethane offers properties, such as outstanding abrasion resistance, excellent low temperature flexi …
  • デジタルX線の世界市場:マンモグラフィー、歯科、胸部X線撮影、心血管、整形外科用途
    The global digital radiography market consists of various products that are used in for diagnostic imaging. This market is driven by several factors such as rising aging population and technological advancements. High potential growth in emerging markets have opened an array of opportunities for the market. However, high cost of digital x-ray is hampering the growth of the global market. The digit …
  • 世界の消費者向けNAS市場動向(2012-2016)
    TechNavio's analysts forecast the Global Consumer NAS market to grow at a CAGR of 14.7 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapid growth in digital content globally. The Global Consumer NAS market has also been witnessing the increasing adoption of video surveillance services for households. However, the lack of technical knowledge abo …
  • Congestive Heart Failure (Heart Failure):グローバル臨床試験レビューH1, 2013
    Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013" provides data on the Congestive Heart Failure (Heart Failure) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congestive Heart F …
  • フランスの移動補助・運搬機器市場見通し(~2021)
    France Mobility Aids and Transportation Equipment Market Outlook to 2021 Summary GlobalData’s new report, "France Mobility Aids and Transportation Equipment Market Outlook to 2021", provides key market data on the France Mobility Aids and Transportation Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market se …
  • 自動車クラッチの世界市場:種類別(マニュアルトランスミッション、AT、AMT、CVT)、クラッチディスク別、地域別分析
    A clutch is a mechanism that is used to connect the driving shaft to a driven shaft, so that the driven shaft may be started or stopped at will without stopping the driving shaft. A clutch thus provides a separable connection between two rotating shafts. It is used in a transmission system to connect the engine and the gear box so that the engine can be started or stopped while disengaging the tra …
  • バーチャル網膜ディスプレイの世界市場2016-2020
    About Global Virtual Retinal Display MarketVRD, also called as retinal scan display (RSD), is a display technology that uses power laser beam as a light source, which is projected onto the retina of the user. The VRD scans the images on the retina of the user to display images in real-time. Technavio’s analysts forecast the global virtual retinal display market to grow at a CAGR of 3.64% during th …
  • 世界のコンテンツ・デリバリー・ネットワーク市場(2012-2016)
    TechNavio's analysts forecast the Global Content Delivery Network market to grow at a CAGR of 15.73 percent over the period 2012-2016. One of the key factors contributing to this market growth is the uninterrupted availability of content facilitated by content delivery networks. The Global Content Delivery Network market has also been witnessing increasing development of cloud-based content delive …
  • 消毒器の世界市場
    About Disinfectors Disinfectors are used for destroying pathogens for controlling infection. Disinfectors are equipment used for cleaning and sterilizing medical devices and for ensuring hygiene. Disinfectors are used to disinfect and sterilize various medical instruments such as surgical instruments, bedpans, urine bottles, waste containers, and endoscopes. The use of disinfectors ensures the hyg …
  • 骨内注入用機器の世界市場2017-2021
    About Intraosseous Infusion Devices Market The global intraosseous infusion devices market is growing steadily, primarily due to rise in emergency medical cases, which manage critical or life threatening conditions. The market is driven by the rise in the incidence of chronic disorders such as cardiovascular diseases, traumatic injuries, severe burns, and obesity. Intraosseous devices have a high …
  • Abraxas Petroleum Corporation:石油・ガスの開発・生産動向及びコスト分析– Q1, 2013
    Abraxas Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis – Q1, 2013 Summary Abraxas Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an …
  • Tetra Technologies, Inc.:石油・ガスの開発・生産動向及びコスト分析- 2012
    Tetra Technologies, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Tetra Technologies, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
  • 自閉症(Autism):グローバル臨床試験レビュー(2014年上半期)
    Autism Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction ac …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。